Mont-Saint-Guibert

Information on the total number of voting rights and shares

Retrieved on: 
Friday, March 29, 2024
Disclosure, ESOP, Mont-Saint-Guibert, Brussels Stock Exchange, Security (finance)

Mont-Saint-Guibert (Belgium), March 29, 2024, 9:30 pm CET / 4:30 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.

Key Points: 
  • Mont-Saint-Guibert (Belgium), March 29, 2024, 9:30 pm CET / 4:30 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.
  • Total number of securities carrying voting rights: 28,682,635 (all ordinary shares)
    Number of rights to subscribe to securities carrying voting rights not yet issued:
    100 “2018 ESOP Warrants” issued on December 12, 2018, entitling their holders to subscribe to a total number of 50,000 securities carrying voting rights (all ordinary shares);
    400,500 “2020 ESOP Warrants” issued on February 21, 2020, entitling their holders to subscribe to a total number of 400,500 securities carrying voting rights (all ordinary shares); and
    1,085,500 “2021 ESOP Warrants” issued on September 8, 2021, entitling their holders to subscribe to a total number of 1,085,500 securities carrying voting rights (all ordinary shares); and
    700,000 “2022 ESOP Warrants” issued on December 28, 2022, entitling their holders to subscribe to a total number of 700,000 securities carrying voting rights (all ordinary shares).

Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation

Retrieved on: 
Monday, March 25, 2024
OSA, Growth, Otorhinolaryngology, Partnership, Patient, Mont-Saint-Guibert, Insurance, Euronext, AAO, Obstructive sleep apnea, CMS, Corporation, Pharmaceutical industry

Nyxoah is the first medical device company to partner with the AAO-HNSF at this level.

Key Points: 
  • Nyxoah is the first medical device company to partner with the AAO-HNSF at this level.
  • The AAO-HNSF is committed to identifying and combating harmful coverage policies that threaten access to quality otolaryngology-head and neck services.
  • The Academy’s Advocacy team, in collaboration with its dedicated members and strategic industry partners like Nyxoah, actively engage with payers to achieve this goal.
  • “Nyxoah and the AAO-HNSF share the common goal of putting patients first and making sure they have access to HGNS therapy.

Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints

Retrieved on: 
Tuesday, March 19, 2024
DREAM, OSA, Annual report, ODI, Patient, PSG, Mont-Saint-Guibert, IDE, AHI, Euronext, ITT, Oxygen, Obstructive sleep apnea, Pharmaceutical industry

The DREAM study is a pivotal trial, being conducted under an investigational device exemption (IDE) and is designed to support the marketing authorization of the Genio® hypoglossal nerve stimulation system (HGNS) in the United States.

Key Points: 
  • The DREAM study is a pivotal trial, being conducted under an investigational device exemption (IDE) and is designed to support the marketing authorization of the Genio® hypoglossal nerve stimulation system (HGNS) in the United States.
  • Study participants entered the DREAM study with a mean AHI of 28.0, mean ODI of 27.0 and mean body mass index of 28.5.
  • “DREAM is a pivotal, multicenter, international study of Genio, a next generation HGNS technology offering patients bi-lateral stimulation with a non-implanted battery solution powered and controlled by a wearable.
  • A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: DREAM Results Webcast .

Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Retrieved on: 
Thursday, February 29, 2024
Obstructive sleep apnea, Euronext, Conference, OSA, Medtech, Mont-Saint-Guibert

Mont-Saint-Guibert, Belgium – February 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference, which takes place March 12 – 13, 2024.

Key Points: 
  • Mont-Saint-Guibert, Belgium – February 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference, which takes place March 12 – 13, 2024.
  • Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate presentation on Tuesday, March 12, 2024, at 10:40am ET.
  • A webcast of the presentation will be available in the Events section of Nyxoah’s Investor Relations website.
  • Nyxoah’s Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.

Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024

Retrieved on: 
Thursday, February 15, 2024
Obstructive sleep apnea, Finance, Euronext, Webcast, Fiscal year, OSA, Mont-Saint-Guibert

Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024

Key Points: 
  • Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024
    Mont-Saint-Guibert, Belgium – February 15, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the fourth quarter and financial year 2023 on Tuesday, March 5, 2024, after market close.
  • Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.
  • A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q4 2023 earnings call webcast .
  • If you plan to ask a question, please use the following link: Nyxoah’s Q4 2023 earnings call .

Nyxoah Announces 2024 Strategic Priorities

Retrieved on: 
Wednesday, January 17, 2024
DREAM, ResMed, Patient, Euronext, CCC, Partnership, Mont-Saint-Guibert, AHI, Obstructive sleep apnea, ODI, DTC, Investment, CPAP, OSA, Safety, PMA, Growth, Pharmaceutical industry

Mont-Saint-Guibert, Belgium – January 17, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced, in anticipation of upcoming investor meetings, its strategic priorities for 2024.

Key Points: 
  • Mont-Saint-Guibert, Belgium – January 17, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced, in anticipation of upcoming investor meetings, its strategic priorities for 2024.
  • Complete patient follow up in the DREAM U.S. pivotal study and report efficacy and safety data by early April.
  • Accelerate investments in the U.S. commercial organization in preparation for a late 2024 launch.
  • For 2024, we expect continued sales growth driven by an increasing benefit from direct-to-consumer (DTC) initiatives, initial contribution from the ResMed commercial partnership in Germany and geographic expansion.

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023

Retrieved on: 
Tuesday, January 9, 2024
DREAM, ResMed, Euronext, Annual report, Partnership, Mont-Saint-Guibert, Obstructive sleep apnea, OSA, FDA, Growth

Mont-Saint-Guibert, Belgium – January 9, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Mont-Saint-Guibert, Belgium – January 9, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2023.
  • Revenue for the fourth quarter of 2023 is anticipated to be approximately €1.8 million, a 40% increase over the fourth quarter of 2022 and an 87% increase over the third quarter of 2023.
  • Revenue for the full year 2023 is anticipated to be approximately €4.3 million, a 41% increase over the full year 2022.
  • “We are excited with the strong preliminary fourth quarter sales, which are anticipated to be nearly double from last quarter.

Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®

Retrieved on: 
Monday, December 11, 2023
Mont-Saint-Guibert, Conference, Obstructive sleep apnea, FDA, Epworth Sleepiness Scale, ESS, Euronext, Patient, AHI, CCC, Medical device

The investigator-sponsored case series was presented by Dr. Christian Plettenberg from the Universitätsklinikum Düsseldorf on December 8, 2023.

Key Points: 
  • The investigator-sponsored case series was presented by Dr. Christian Plettenberg from the Universitätsklinikum Düsseldorf on December 8, 2023.
  • Results showed an average apnea-hypopnea index (AHI) decrease of 73% and Epworth Sleepiness Scale (ESS) decrease of 58%.
  • “These data further validate Genio’s bilateral stimulation approach in treating CCC patients, who represent approximately 30% of HGNS eligible-to-treat OSA patients and are contraindicated to commercially available HGNS therapy in the US.
  • “I want to thank Dr. Plettenberg and his colleagues for their important work which reinforces Genio as a treatment solution for both non-CCC and CCC patients.”

Publication Relating to a Transparency Notification

Retrieved on: 
Friday, December 8, 2023
Disclosure, Euronext, Person, Mont-Saint-Guibert, Nightclub

Mont-Saint-Guibert (Belgium), December 8, 2023, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

Key Points: 
  • Mont-Saint-Guibert (Belgium), December 8, 2023, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.
  • On December 6, 2023, Nyxoah received a transparency notification from Deerfield Partners, L.P. indicating that Deerfield Partners, L.P. crossed the 3% threshold on November 30, 2023, after which Deerfield Partners, L.P. holds 856,085 shares, representing 2.99% of the total number of voting rights on November 30, 2023 (28,673,985).
  • The notification dated December 6, 2023 contains the following information:
    Persons subject to the notification requirement:
    Deerfield Partners, L.P. (with address at 345 Park Ave S., 12th FL, New York, NY 10010 United States)
    Deerfield Mgmt, L.P. (with address at 345 Park Ave S., 12th FL, New York, NY 10010 United States)
    J.E.
  • Flynn Capital, LLC (with address at 345 Park Ave S., 12th FL, New York, NY 10010 United States)
    Deerfield Management Company, L.P. (with address at 345 Park Ave S., 12th FL, New York, NY 10010 United States)
    Flynn Management LLC (with address at 345 Park Ave S., 12th FL, New York, NY 10010 United States)
    Date on which the threshold was crossed: November 30, 2023

Nyxoah Strengthens its Executive Leadership Team

Retrieved on: 
Tuesday, November 28, 2023
DREAM, Mont-Saint-Guibert, Obstructive sleep apnea, FDA, Euronext, Quality, Medtronic, Investment, OSA, PMA, Pharmaceutical industry

Francis will be leading Nyxoah’s Global Regulatory and Quality departments.

Key Points: 
  • Francis will be leading Nyxoah’s Global Regulatory and Quality departments.
  • Francis is a highly experienced global regulatory and quality executive in the healthcare industry, having spent more than 25 years in the medical device and life sciences sector.
  • Francis has led Regulatory and Quality departments at Medtronic, Philips, and other companies, including introducing several innovative products and therapies to the market.
  • I am excited having someone with Francis’ regulatory and quality experience joining Nyxoah at this important time, and I look forward to continued investments as we prepare to for a U.S. market entrance,” commented Olivier Taelman, Nyxoah Chief Executive Officer.